Navigation Links
OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Date:8/3/2009

BOTHELL, WA and VANCOUVER, Aug. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals (NASDAQ: OGXI) announced today that the Company will announce second quarter financial results on Thursday, August 6, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. EDT that afternoon to discuss quarterly results.

The webcast can be accessed on the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7912 (U.S. Canada) or 719-325-4897 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
3. OncoGenex Pharmaceuticals Added to Russell Indexes
4. OncoGenex Pharmaceuticals Files Shelf Registration Statement
5. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
6. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
7. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
8. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
9. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
10. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
11. OncoGenex Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed ... seed this week with the release of their Pearl's ... the fact that it is time to plant now ... , As of the date 6/4/13, Pearl's Premium had ... experts and the media including: The National Gardeners ...
(Date:9/22/2014)... job it is to stop bleeding, are very simple. ... "feel" the physical environment around them, researchers at Emory ... surfaces with greater stiffness by increasing their stickiness, the ... other components of the clotting system, the researchers found. ... for, in that they are able to sense the ...
(Date:9/22/2014)... to create a highly sensitive chemical sensor based on ... unique electronic properties that the researchers were able to ... 300 times. , The study is available online in ... Amin Salehi- Khojin, asst professor of mechanical and industrial ... and Bijandra Kumar, post doc where they are doing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Topical BioMedics, ... those in pain end their suffering, restoring hope an ... model. This is only possible because of the innovative ... healing cream technology a reality. , The company ... NY, by Lou Paradise (president, chief of research, and ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... West Central Wisconsin Workforce Resource is inviting representatives ... Synergy Conference titled "Positioning for Economic Growth." , ,The conference ... a.m. to 5 p.m. and Sept. 21 from 8 a.m. ... Memorial Student Center . , ,Although some speakers have ...
... - Mithridion, Inc. , a biopharmaceutical startup that is ... secured $296,800 in federal grants to evaluate tests for drug ... Institute on Aging , a branch of the U.S. ... the feasibility of the tests. If successful, the company will ...
... Wis. - The recent decision by a young researcher ... some of the financial consequences of the same-sex union debate ... and nanotechnology researcher, has won $3.4 million in grants since ... year, he will take his knowledge and research with him ...
Cached Biology Technology:Conference to address small town development 2Mithridion wins grants for Alzheimer's research 2Mithridion wins grants for Alzheimer's research 3Departure of nanotech researcher stings UW 2Departure of nanotech researcher stings UW 3
(Date:9/21/2014)... to what was previously thought, newborn immune T cells ... to bacteria, according to a new study led by ... differently to that of adults, babies may still be ... study published in the journal Nature Medicine . ... different types of immune cells, including neutrophils which play ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... were not the only ones with visions of sugar plums ... a new research report published in the January 2010 issue ... ), a team of scientists from the University of Texas ... compound from licorice root (glycyrrhizin from Glycyrrhiza glabra ) ...
... DALLAS Jan. 4, 2010 An experimental drug currently ... fighting the brain cancer glioblastoma and prostate cancer, researchers at ... The drug,s actions, observed in isolated human cells in ... encouraging because they attacked not only the bulk of the ...
... origin of the Devil Facial Tumour Disease (DFTD) that has ... scientists has discovered. Devil Facial Tumour Disease (DFTD) ... was first reported in 1996. It is spread by biting ... large tumours, mostly on the face and mouth, which often ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Experimental drug shows promise against brain, prostate cancers 2Nervous culprit found for Tassie devil facial tumor disease 2
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... (Thr183/Tyr185) Antibody, Catalog #9251, 200 ul ... 200 ul SAPK/JNK Cell Extracts, Catalog ... HRP-linked Antibody, Catalog #7074, 100 ul ...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: